tradingkey.logo

Regeneron Pharmaceuticals Says FDA Extends EYLEA HD Decision To Late 2025

ReutersAug 20, 2025 3:38 PM

- Regeneron Pharmaceuticals Inc REGN.O:

  • EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG APPLICATIONS FOR EXPANDED U.S. LABEL AND PREFILLED SYRINGE RECEIVE FDA REVIEW PERIOD EXTENSION

  • REGENERON PHARMACEUTICALS INC - FDA EXTENDS TARGET ACTION DATES FOR EYLEA HD TO Q4 2025

  • REGENERON PHARMACEUTICALS INC - FDA EXTENDED REVIEW DUE TO MAJOR AMENDMENT FROM THIRD-PARTY INSPECTION

  • REGENERON PHARMACEUTICALS INC: EYLEA HD REMAINS AVAILABLE IN U.S. THROUGH VIAL ADMINISTRATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI